The study will assess the efficacy and safety of zorevunersen compared to sham over a 52-week treatment period.

The Brennan family will host the 7th Annual Dance for Dravet on September 26th at the Third Degree Glass Factory to raise ...

The global Phase III EMPEROR trial (NCT06872125) will evaluate the safety and efficacy of zorevunersen, a novel antisense ...

Cambridge, Massachusetts Wednesday, August 13, 2025, 15:00 Hrs [IST] ...

Stoke Therapeutics Inc (STOK) reports promising advancements in its Dravet syndrome program and strategic partnerships, ...

Stoke Therapeutics ( ($STOK) ) has released its Q2 earnings. Here is a breakdown of the information Stoke Therapeutics presented to its investors.

HONG KONG SAR - Media OutReach Newswire - 8 August 2025 - Bora Pharmaceuticals (TWSE: 6472) today announced its financial ...

Analysts have given Stoke Therapeutics a total of 3 ratings, with the consensus rating being Buy. The average one-year price target is $29.0, indicating a potential 121.37% upside.

August 5, 2025Harmony Biosciences Holdings, Inc. misses on earnings expectations. Reported EPS is $0.681 EPS, expectations ...

Detailed price information for Xenon Pharmaceuticals Inc (XENE-Q) from The Globe and Mail including charting and trades.

Biogen has bolstered its pipeline by licensing ex-US rights to a drug for Dravet syndrome – a rare form of epilepsy – from Stoke Therapeutics in a deal that included an upfront payment of $165 ...

Cardiol's CardiolRx did not have a significant impact on left ventricular extracellular volume (LV-ECV) in the Phase II ARCHER study.